Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Ueta, Mayumi ^a,b   Kaniwa, Nahoko ^c   Sotozono, Chie ^a   Tokunaga, Katsushi ^d   Saito, Yoshiro ^c   Sawai, Hiromi ^d   Miyadera, Hiroko ^d   Sugiyama, Emiko ^c   Maekawa, Keiko ^c   Nakamura, Ryosuke ^c   Nagato, Masaki ^e   Aihara, Michiko ^f   Matsunaga, Kayoko ^g   Takahashi, Yukitoshi ^h   Furuya, Hirokazu ⁱ   Muramatsu, Masaaki ^j   Ikezawa, Zenrou ^k   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

ⁱ KOCHI MEDICAL SCHOOL   (Japan)

^j TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^k INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUCOSA; PATHOLOGY; STEVENS JOHNSON SYNDROME; VISUAL DISORDER; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CHILD; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; STEVENS-JOHNSON SYNDROME; VISION DISORDERS; YOUNG ADULT;

EID: 84899845666     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04862     Document Type: Article

References (28)

1. Ueta, M. et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 91, 962-965 (2007).
2. Yamane, Y., Aihara, M. & Ikezawa, Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 56, 419-425 (2007).
3. Yetiv, J. Z., Bianchine, J. R. & Owen, J. A., Jr. Etiologic factors of the Stevens-Johnson syndrome. South Med J 73, 599-602 (1980).
4. Roujeau, J. C. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333, 1600-1607 (1995).
5. Chan, H. L. et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126, 43-47 (1990).
6. Power, W. J., Ghoraishi, M., Merayo-Lloves, J., Neves, R. A. & Foster, C. S. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 102, 1669-1676 (1995).
7. Chung, W. H. et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
8. Ozeki, T. et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Molec Genetics 20, 1034-1041, DOI:10.1093/hmg/ddq537 (2011).
9. McCormack, M. et al.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364, 1134-1143, DOI:10.1056/NEJMoa1013297 (2011).
10. Hung, S. I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102, 4134-4139 (2005).
11. Lonjou, C. et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18, 99-107 (2008).
12. Tohkin, M. et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 13, 60-69, DOI:10.1038/tpj.2011.41 (2013).
13. Mockenhaupt, M. et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128, 35-44, DOI:10.1038/sj.jid. 5701033 (2008).
14. Ueta, M. et al. Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. J Allergy Clin Immunol 126, 1218-1225 e1210, DOI:10.1016/j.jaci.2010.08.007 (2010).
15. Ueta, M. et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 14, 550-555 (2008).
16. Bastuji-Garin, S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythemamultiforme. Arch Dermatol 129, 92-96 (1993).
17. Kawashima, M., Ohashi, J., Nishida, N. & Tokunaga, K. Evolutionary analysis of classical HLA class I and II genes suggests that recent positive selection acted on DPB1*04:01 in Japanese population. PloS one 7, e46806, DOI:10.1371/journal.pone.0046806 (2012).
18. Nakaji, S., Ueta, M., Sotozono, C., Inatomi, T. & Kinoshita, S. [HLA-class I gene polymorphisms in Japanese Stevens-Johnson syndrome patients with ocular surface complications]. Nippon Ganka Gakkai Zasshi 116, 581-587 (2012).
19. Ueta, M., Sotozono, C., Tokunaga, K., Yabe, T. & Kinoshita, S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 143, 367-368 (2007).
20. Tokunaga, K. et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 46, 199-205 (1997).
21. Middleton, D., Menchaca, L., Rood, H. & Komerofsky, R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61, 403-407 (2003).
22. Mondino, B. J., Brown, S. I. & Biglan, A. W. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol 100, 1453-1454 (1982).
23. Roujeau, J. C. et al. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 28, 251-254 (1986).
24. Roujeau, J. C. et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 123, 1171-1173 (1987).
25. Forman, R., Koren, G. & Shear, N. H. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A review of 10 years' experience. Drug safety 25, 965-972 (2002).
26. Leaute-Labreze, C., Lamireau, T., Chawki, D., Maleville, J. & Taieb, A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Childhood 83, 347-352 (2000).
27. Ueta, M. et al.HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications. PloS one 7, e43650, DOI:10.1371/journal.pone.0043650 (2012).
28. Ueta, M., Sotozono, C., Yokoi, N., Inatomi, T. & Kinoshita, S. Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders. PloS one 6, e25209, DOI:10.1371/journal.pone.0025209 (2011).